Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02781792 : Temozolomide Chronotherapy for High Grade Glioma
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Newly diagnosed and recurrent high grade gliomas (WHO grades III & IV) and high risk
WHO grade II gliomas who are to begin treatment with monthly high dose temozolomide
therapy.

- Scheduled to receive adjuvant temozolomide therapy after having completed concurrent
temozolomide and radiation therapy.

- At least 18 years of age.

- Karnofsky performance status = 60%

- Ability to understand and willingness to sign an IRB approved written informed consent
document

Exclusion Criteria:.

-Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
pregnancy test within 14 days of study entry.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02781792      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740